Soligenix Inc. Advances in Rare Disease Therapeutics with HyBryte(TM) Platform
August 5th, 2025 2:18 PM
By: Newsworthy Staff
Soligenix Inc. is making significant progress in developing treatments for rare diseases, particularly cutaneous T-cell lymphoma, with its HyBryte(TM) platform, addressing a critical need for FDA-approved therapies in an underserved demographic.
Soligenix Inc. (NASDAQ: SNGX) has recently been spotlighted for its advancements in the field of rare disease therapeutics, specifically through its HyBryte(TM) platform aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer predominantly affecting older adults. This development is particularly significant given the urgent need for effective treatments, as over 30 million Americans live with rare conditions, many of which lack FDA-approved therapies.
The company's successful domestic manufacturing of HyBryte's active ingredient marks a pivotal step forward in its mission to provide innovative, U.S.-based therapies for this underserved population. The HyBryte(TM) platform, also known as SGX301 or synthetic hypericin, represents a novel photodynamic therapy that utilizes safe visible light for the treatment of CTCL. With the completion of a second Phase 3 study, Soligenix is now poised to seek regulatory approvals to support the potential commercialization of HyBryte worldwide.
Beyond CTCL, Soligenix is exploring the expansion of synthetic hypericin into other areas, such as psoriasis, and is developing first-in-class innate defense regulator technology for inflammatory diseases. The company's Public Health Solutions business segment is also making strides with vaccine candidates targeting ricin toxin, filoviruses, and COVID-19, supported by government grants and contracts. For more information on Soligenix's innovative approaches to rare diseases and public health challenges, visit https://www.Soligenix.com.
The progress of Soligenix in the rare disease sector underscores the importance of continued investment and innovation in biopharmaceutical research. As the company moves closer to potential commercialization of its therapies, the implications for patients with rare diseases are profound, offering hope for treatments where few or none exist. For the latest updates on Soligenix's developments, the company's newsroom can be accessed at https://ibn.fm/SNGX.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
